Spago Nanomedical AB (publ) (STO:SPAGO)
Sweden · Delayed Price · Currency is SEK 0.1090
-0.0035 (-3.11%)
Sep 4, 2026, 10:32 AM CET
Spago Nanomedical AB Earnings Call Transcripts
Fiscal Year 2026
-
A novel nanoparticle radiopharmaceutical platform is advancing through clinical trials, showing promising tumor uptake and safety in head and neck cancers. Plans include Orphan Drug Designation for ACC, expansion into the U.S. market, and active partnership outreach, with pivotal trial preparations underway.
Fiscal Year 2025
-
A novel radiopharmaceutical platform is advancing clinical trials in Australia, showing promising tumor uptake and a favorable safety profile. The technology targets multiple tumor types, including rare cancers, and is supported by ongoing capital raising and plans for accelerated development.